Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 432

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 432
---
out shares (the “Earnout
Shares”) of Class A common stock, one pool of which will contain 875,000 shares, which will be fully vested at closing of the Business
Combination and which are being issued as an offset to the agreement by Sponsor to forfeit an offsetting number of shares, and one pool
of which will contain 1,000,000 shares, which will be fully vested upon the achievement of certain regulatory milestone-based earnout
targets and make certain other technical changes to the timing and process for issuance of the 1,200,000 shares of Class A common stock
subject to the other earn-out conditions set forth in the Business Combination Agreement.

The Business Combination closed on February 14,
2024, at which time the following occurred:

| 1. | Each outstanding share                                                                                                     
 of the Company’s convertible preferred stock was converted into the number of shares of Class A common stock calculated by 
 dividing the liquidation preference by $10.00.                                                                             |

| 2. | Each outstanding share                                                                                                           
 of the Company’s common stock was converted into the number of shares of Class A common stock calculated by multiplying each     
 share by the exchange ratio (the “Exchange Ratio”). The Exchange Ratio of 0.064452 was calculated by first subtracting           
 the aggregate liquidation preference of outstanding preferred shares from $50 million, then dividing the result by the number of 
 shares of the Company’s common stock outstanding and dividing by $10.00 per share.                                               |

| 3. | Each holder of the Company’s                                                                                                                 
 common stock received a pro rata portion of up to 1.2 million Earnout Shares, 1,000,000 of which are subject to vesting upon the             
 achievement of certain stock price-based earnout targets and 200,000 of which are subject to vesting upon a change of control, respectively. |

| 4. | Certain holders of the                                                                                                      
 Company’s common stock received a pro rata portion of 875,000 Earnout Shares, which became fully vested upon the closing of 
 the Business Combination.                                                                                                   |

<div align='center'>F-67

CERo Therapeutics, Inc.

Notes to Financial Statements</div>

| 5. | Certain holders of the                                                                                                        
 Company’s common stock received a pro rata portion of up to 1.0 million Earnout Shares, which are subject to vesting upon the 
 Company’s filing an investigational new drug application with